| Literature DB >> 27641944 |
Zeinab Hosseinidoust1, Babak Mostaghaci1, Oncay Yasa1, Byung-Wook Park1, Ajay Vikram Singh1, Metin Sitti2.
Abstract
The use of bacterial cells as agents of medical therapy has a long history. Research that was ignited over a century ago with the accidental infection of cancer patients has matured into a platform technology that offers the promise of opening up new potential frontiers in medical treatment. Bacterial cells exhibit unique characteristics that make them well-suited as smart drug delivery agents. Our ability to genetically manipulate the molecular machinery of these cells enables the customization of their therapeutic action as well as its precise tuning and spatio-temporal control, allowing for the design of unique, complex therapeutic functions, unmatched by current drug delivery systems. Early results have been promising, but there are still many important challenges that must be addressed. We present a review of promises and challenges of employing bioengineered bacteria in drug delivery systems and introduce the biohybrid design concept as a new additional paradigm in bacteria-based drug delivery.Entities:
Keywords: Bacteria; Bactofection; Biohybrid; Cell therapy; Engineered; Gene therapy; Microbial factories; Microrobotics; Synthetic biology; Tumor targeting
Mesh:
Substances:
Year: 2016 PMID: 27641944 DOI: 10.1016/j.addr.2016.09.007
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470